IP Library Patent Application 15346844
Patent Application
App. No. 15/346,844

USE OF ONE OR A COMBINATION OF PHYTO-CANNABINOIDS IN THE TREATMENT OF EPILEPSY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/346,844
Abstract

This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.

Claims (14)

1 .- 10 . (canceled)

11 . A method of treating complex partial seizure that remains localized comprising administering cannabidiol (CBD) to a patient wherein the CBD is present in an amount which provides a daily dose of at least 400 mg.

12 . The method of claim 11 , wherein CBD is present in an amount which provides a daily dose of from 400 to 800 mg.

13 . The method of claim 11 , wherein the CBD is used in combination with tetrahydrocannabivarin (THCV).

14 . The method of claim 13 , wherein the THCV is present in an amount which provides a daily dose of at least 1.5 mg.

15 . he method of claim 14 , wherein the THCV is present in an amount which provides a daily dose of at least 15 mg.

16 . The method of claim 11 , wherein the CBD is present as a plant extract.

17 . The method of claim 16 , wherein the plant extract comprises less than 5% by weight of tetrahydrocannabinol (THC) as a percentage of any cannabinoids present in the plant extract.

18 . The method of claim 17 , wherein the plant extract comprises less than 1% by weight of tetrahydrocannabinol (THC) as a percentage of any cannabinoids present in the plant extract.

19 . The method of claim 11 , wherein the CBD is present as a pure or isolated cannabinoid.

20 . The method of claim 13 , wherein the CBD in combination with THCV is present as a plant extract.

21 . The method of claim 20 , wherein the plant extract comprises less than 5% by weight of tetrahydrocannabinol (THC) as a percentage of any cannabinoids present in the plant extract.

22 . The method of claim 21 , wherein the plant extract comprises less than 1% by weight of tetrahydrocannabinol (THC) as a percentage of any cannabinoids present in the plant extract.

23 . The method of claim 13 , wherein the CBD in combination with THCV is present as a pure or isolated cannabinoid.

Assignments (3)
REMOVE PAT NO 9,066,920 AT REEL/FRAME 044162/0001 -- THE DEED OF ASSIGNMENT RECORDED AT REEL/FRAME 044162/0001 DID NOT CONVEY PAT NO 9,066,920 Recorded Nov 7, 2018
From: OTSUKA PHARMACEUTICAL CO., LIMITED
To: GW PHARMA LIMITED
Reel/Frame 048407/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2017
From: OTSUKA PHARMACEUTICAL CO., LIMITED
To: GW PHARMA LIMITED
Reel/Frame 044162/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 6, 2017
From: WHALLEY, BENJAMIN; STEPHENS, GARY; WILLIAMS, CLAIRE; GUY, GEOFFREY; WRIGHT, STEPHEN; KIKUCHI, TETSURO
To: GW PHARMA LIMITED; OTSUKA PHARMACEUTICAL CO., LIMITED
Reel/Frame 041475/0185 →